Menzel Garry E
SEC-identified person · CIK 1556064 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Black Diamond Therapeutics, Inc. BDTX | Director | filed 2020 - 2026 |
| Stoke Therapeutics, Inc. STOK | Director | filed 2021 - 2025 |
| Adaptimmune Therapeutics PLC ADAP] | Director | filed 2023 - 2024 |
| TCR2 Therapeutics INC. TCRR | Director · President and CEO | filed 2019 - 2023 |
| Davita INC. DVA | Senior Vice President, Finance | filed 2013 - 2013 |
| Regulus Therapeutics Inc. RGLS | COO & Executive VP, Finance | filed 2012 - 2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.